The multidisciplinary approach to thymoma: combining molecular and clinical approaches.
Thymomas are rare epithelial tumors that display significant heterogeneity. Thymomas are usually indolent; however, thymic carcinomas are typically invasive with a high risk of relapse and death. Current treatment approaches are primarily based on clinical stage. Surgery is the mainstay for treatment of early stage disease, whereas multimodality therapy is required for advanced disease. The most important prognostic factors are stage and histology; however, increasing recognition of disease heterogeneity has led to recent exploration of underlying molecular mechanisms. Molecular characterization of thymic tumors may offer strategies to improve diagnosis, therapy, and prognosis. This article describes recently identified molecular characteristics of thymoma and thymic carcinoma that may potentially impact disease classification, targeted therapeutic decision making, and design of future clinical trials.
Chau
Nicole G
NG
Division of Medical Oncology and Hematology, University of Toronto, Toronto, Canada.
Kim
Edward S
ES
Wistuba
Ignacio
I
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D013945:Thymoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D013953:Thymus Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins